Fecundis at ESHRE 2026: Bringing Sperm Biology Into the IVF Conversation
Fecundis joined ESHRE 2026 in London, presenting HyperSperm and discussing the growing role of sperm biology, capacitation, and functional sperm preparation in the future of IVF.
Biology-Inspired Sperm Selection: Can It Improve Embryo Quality in ICSI?
A new ICSI study suggests that cumulus cell-mediated sperm selection may improve blastocyst rates, highlighting the importance of sperm physiology beyond motility and morphology.
New Clinical Evidence Shows HyperSperm™ Improves Blastocyst Yield and Embryo Quality in IVF
A new multicenter clinical study published in Journal of Translational Medicine shows that HyperSperm improves blastocyst yield and embryo quality in IVF patients.
PROYECTO DESARROLLO DE UN DISPOSITIVO AUTOMATIZADO AVANZADO PARA LA SELECCIÓN Y MEJORA FUNCIONAL DE ESPERMATOZOIDES EN TRATAMIENTOS DE FERTILIZACIÓN IN VITRO liderado por FECUNDIS LAB ,S.L (Nº Expediente: EXP – 00175630 / CIIP-20251002)
Fecundis Lab, en colaboración con Beonchip S.L. (España) y la clínica danesa Fertilitets Klinikken Lygten, trabaja en el desarrollo de HyperFlow: un dispositivo totalmente automatizado capaz de seleccionar y mejorar funcionalmente los espermatozoides, con el objetivo de incrementar las tasas de éxito en reproducción asistida humana.
Fecundis Presented HyperSperm Clinical Data at REDLARA 2026
Fecundis participated in REDLARA 2026, presenting clinical data on HyperSperm showing improved blastocyst formation and euploidy rates in IVF and ICSI cycles.
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking “Accept All”, you consent to our use of cookies.
You can change or withdraw your consent at any time using the privacy settings button.
